Pediatric clinical trial studies antibody treatment for various types of solid tumors
A clinical trial for pediatric patients will test the safety and efficacy of enoblituzumab in solid tumors that express B7-H3, a protein that helps to regulate T cells.
Photo credit: Rhoda Baer
A new study aims to test the safety and efficacy of enoblituzumab in solid tumors that express B7-H3, including but not limited to neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, Wilms tumor, or desmoplastic small round cell tumor. B7-H3 is a protein that helps to regulate T cells, which are part of the immune system. Enoblituzumab is an antibody that targets B7-H3 and promotes the attack of cancer cells. Leading the Macrogenics-sponsored study, Rosandra Kaplan, M.D., of the Pediatric Oncology Branch hopes to determine if enoblituzumab can both directly target tumor cells as well as help T cells attack tumors that express high amounts of B7-H3.
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow by treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland. Search all CCR clinical trials, and subscribe to have the latest CCR clinical trials sent to your inbox.Summary Posted: Wed, 11/01/2017